EC Gynaecology

Introduction

Women's health encompasses a broad spectrum of physical, mental, and social well-being throughout the lifespan. As we strive to promote equity and excellence in healthcare, it is crucial to recognize the multifaceted nature of women's health needs and advocate for a comprehensive approach to gynaecological care. Polycystic Ovary Syndrome (PCOS) stands as one of the most common endocrine disorders affecting reproductive-aged women worldwide [1]. Despite its prevalence and significant impact on women's health, there remains a myriad of challenges in its diagnosis, management, and long-term implications. As the medical community continues to delve into the complexities of PCOS, it is imperative to highlight the multifaceted nature of this syndrome and advocate for a holistic approach to patient care. PCOS is a complex endocrine disorder characterized by hormonal imbalances, ovarian dysfunction, and metabolic disturbances [2]. While PCOS presents with heterogeneous clinical manifestations, its underlying mechanisms of disease progression remain an area of active research. Understanding the intricate interplay of genetic, hormonal, and environmental factors contributing to PCOS pathogenesis is essential for elucidating its progression and developing targeted therapeutic interventions.

1. Teede H., et al. “Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome”. Fertility and Sterility3 (2018): 364-379.
2. Diamanti-Kandarakis E and Dunaif A. “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications”. Endocrine Reviews6 (2012): 981-1030.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)”. Human Reproduction1 (2004): 41-47.
4. Legro RS., et al. “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline”. The Journal of Clinical Endocrinology and Metabolism12 (2013): 4565-4592.
5. Azziz R., et al. “The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report”. Fertility and Sterility2 (2006): 456-488.
6. Moran LJ., et al. “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis”. Human Reproduction Update4 (2010): 347-363.
7. Fahs D., et al. “Polycystic ovary syndrome: Pathophysiology and controversies in diagnosis”. Diagnostics (Basel)9 (2023): 1559.
8. Sachdeva G., et al. “Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene”. Indian Journal of Endocrinology and Metabolism 3 (2019): 326-331.
9. Lentscher JA and Decherney AH. “Clinical presentation and diagnosis of polycystic ovarian syndrome”. Clinical Obstetrics and Gynecology 1 (2021): 3-11.
10. Emanuel RHK., et al. “A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions”. Frontiers in Endocrinology (Lausanne) 13 (2022): 1017468.
11. Rosenfield RL and Ehrmann DA. “The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited”. Endocrine Reviews 5 (2016): 467-520.
12. Sanchez-Garrido MA and Tena-Sempere M. “Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies”. Molecular Metabolism 35 (2020): 100937.
13. Mancini A., et al. “Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights”. International Journal of Molecular Sciences 4 (2021): 1667.
14. Cowan S., et al. “Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity”. BMC Endocrine Disorders 1 (2023): 14.
15. Melo AS., et al. “Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice”. Clinics (Sao Paulo)11 (2015): 765-769.
16. O'Kelly AC., et al. “Pregnancy and reproductive risk factors for cardiovascular disease in women”. Circulation Research 4 (2022): 652-672.
17. Singh S., et al. “Polycystic ovary syndrome: Etiology, current management, and future therapeutics”. Journal of Clinical Medicine 4 (2023): 1454.
18. Dewani D., et al. “The invisible struggle: The psychosocial aspects of polycystic ovary syndrome”. Cureus12 (2023): e51321.